TAK vs. OCUL

Last updated Jun 24, 2026

TAK (Takeda Pharmaceutical Company Limited) and OCUL (Ocular Therapeutix, Inc.) are both stocks. Both are in the Healthcare sector — TAK in Drug Manufacturers - Specialty & Generic, OCUL in Biotechnology. Over the past 10 years, TAK returned 0.88%/yr vs 6.94%/yr for OCUL. At a 0.15 correlation, their price movements are largely independent.

Performance

TAK vs. OCUL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Takeda Pharmaceutical Company Limited (TAK) and Ocular Therapeutix, Inc. (OCUL). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TAK achieves a 1.60% return, which is significantly higher than OCUL's -16.68% return. Over the past 10 years, TAK has underperformed OCUL with an annualized return of 0.88%, while OCUL has yielded a comparatively higher 6.94% annualized return.

TAK

• 1D: 2.39%
• 1M: -2.52%
• YTD: 1.60%
• 6M: 2.46%
• 1Y: 10.03%
• 3Y*: 3.51%
• 5Y*: 2.25%
• 10Y*: 0.88%

OCUL

• 1D: 1.45%
• 1M: 22.90%
• YTD: -16.68%
• 6M: -20.60%
• 1Y: 20.85%
• 3Y*: 27.59%
• 5Y*: -7.12%
• 10Y*: 6.94%

*Multi-year figures are annualized to reflect compound growth (CAGR)

TAK vs. OCUL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
TAK Takeda Pharmaceutical Company Limited	1.60%	23.18%	-3.12%	-4.87%	20.08%	-23.45%	-5.18%	22.48%	-38.84%	41.29%
OCUL Ocular Therapeutix, Inc.	-16.68%	42.15%	91.48%	58.72%	-59.68%	-66.33%	424.05%	-0.75%	-10.56%	-46.83%

Correlation

The correlation between TAK and OCUL is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.06
Correlation (3Y) Calculated over the trailing 3-year period	0.14
Correlation (5Y) Calculated over the trailing 5-year period	0.16
Correlation (10Y) Calculated over the trailing 10-year period	0.16
Correlation (All Time) Calculated using the full available price history since Jul 25, 2014	0.15

The correlation between TAK and OCUL shifts across timeframes, from 0.06 (1 year) to 0.16 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap TAK : $49.50B OCUL : $2.27B
EPS TAK : ¥61.03 OCUL : -$1.45
PS Ratio TAK : 1.78 OCUL : 39.05
PB Ratio TAK : 1.02 OCUL : 3.90
Total Revenue (TTM) TAK : ¥4.55T OCUL : $52.04M
Gross Profit (TTM) TAK : ¥2.66T OCUL : $45.40M
EBITDA (TTM) TAK : ¥1.43T OCUL : -$283.03M

Return for Risk

TAK vs. OCUL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TAK

TAK Risk / Return Rank: 54
TAK Sharpe Ratio Rank: 59
TAK Sortino Ratio Rank: 51
TAK Omega Ratio Rank: 50
TAK Calmar Ratio Rank: 54
TAK Martin Ratio Rank: 57

OCUL

OCUL Risk / Return Rank: 53
OCUL Sharpe Ratio Rank: 54
OCUL Sortino Ratio Rank: 56
OCUL Omega Ratio Rank: 55
OCUL Calmar Ratio Rank: 52
OCUL Martin Ratio Rank: 50

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TAK vs. OCUL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Takeda Pharmaceutical Company Limited (TAK) and Ocular Therapeutix, Inc. (OCUL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	TAK	OCUL	Difference
Sharpe ratio: Return per unit of total volatility	0.49	0.30	+0.19
Sortino ratio: Return per unit of downside risk	0.79	1.01	-0.22
Omega ratio: Gain probability vs. loss probability	1.10	1.12	-0.02
Calmar ratio: Return relative to maximum drawdown	0.50	0.37	+0.14
Martin ratio: Return relative to average drawdown	1.35	0.68	+0.66

TAK vs. OCUL - Sharpe Ratio Comparison

The current TAK Sharpe Ratio is 0.49, which is higher than the OCUL Sharpe Ratio of 0.30. The chart below compares the historical Sharpe Ratios of TAK and OCUL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

TAK vs. OCUL - Drawdown Comparison

The maximum TAK drawdown since its inception was -54.25%, smaller than the maximum OCUL drawdown of -95.19%. Use the drawdown chart below to compare losses from any high point for TAK and OCUL.

Drawdown Indicators

	TAK	OCUL	Difference
Max Drawdown Largest peak-to-trough decline	-54.25%	-95.19%	+40.94%
Max Drawdown (1Y) Largest decline over 1 year	-20.05%	-57.29%	+37.24%
Max Drawdown (3Y) Largest decline over 3 years	-20.05%	-61.57%	+41.52%
Max Drawdown (5Y) Largest decline over 5 years	-24.50%	-85.50%	+61.00%
Max Drawdown (10Y) Largest decline over 10 years	-54.25%	-90.94%	+36.69%
Current Drawdown Current decline from peak	-30.30%	-76.62%	+46.32%
Average Drawdown Average peak-to-trough decline	-23.27%	-76.60%	+53.33%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.47%	30.54%	-23.07%

Volatility

TAK vs. OCUL - Volatility Comparison

The current volatility for Takeda Pharmaceutical Company Limited (TAK) is 7.92%, while Ocular Therapeutix, Inc. (OCUL) has a volatility of 17.41%. This indicates that TAK experiences smaller price fluctuations and is considered to be less risky than OCUL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TAK	OCUL	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.92%	17.41%	-9.49%
Volatility (6M) Calculated over the trailing 6-month period	15.33%	54.37%	-39.04%
Volatility (1Y) Calculated over the trailing 1-year period	20.73%	70.06%	-49.33%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	19.58%	78.53%	-58.95%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	23.04%	78.83%	-55.79%

Dividends

TAK vs. OCUL - Dividend Comparison

TAK's dividend yield for the trailing twelve months is around 2.03%, while OCUL has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
OCUL Ocular Therapeutix, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
TAK Takeda Pharmaceutical Company Limited	2.03%	4.24%	4.67%	4.41%	4.23%	2.98%	2.30%	4.20%	4.77%	2.81%	3.99%	2.92%

Financials

Frequently Asked Questions

Can I hold both TAK and OCUL in my portfolio?

TAK and OCUL have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, TAK or OCUL?

OCUL has higher volatility (17.41%) compared to TAK (7.92%). In terms of maximum drawdown, TAK dropped -54.25% vs OCUL's -95.19%.

Which has better risk-adjusted returns?

TAK currently has the higher Sharpe Ratio (0.49 vs 0.30), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.